Non-small-cell lung cancer: Reirradiation for loco-regional relapse previously treated with radiation therapy

被引：58

作者：

Tada T. ^{[1
]}

Fukuda H. ^{[2
]}

Matsui K. ^{[3
]}

Hirashima T. ^{[3
]}

Hosono M. ^{[1
]}

Takada Y. ^{[1
]}

Inoue Y. ^{[1
]}

机构：

[1] Department of Radiology, Osaka City University, Graduate School of Medicine, Abeno-ku, Osaka 545-8585

[2] Department of Radiology, Osaka Prefectural Medical Center for Respiratory and Allergic Disease, Habikino

[3] Department of Thoracic Malignancy, Osaka Prefectural Medical Center for Respiratory and Allergic Disease, Habikino

来源：

International Journal of Clinical Oncology | 2005年 / 10卷 / 4期

关键词：

Non-small-cell lung cancer; Radiation therapy; Reirradiation; Relapse;

D O I：

10.1007/s10147-005-0501-1

中图分类号：

学科分类号：

摘要：

Background. We evaluated the efficacy and toxicity of reirradiation for patients with loco-regional relapse of non-small-cell lung cancer after radiation therapy. Methods. Between 1992 and 2002, 19 patients with loco-regional relapse underwent reirradiation. The median interval between the initial irradiation and reirradiation was 16 months, with a range of 5 to 60 months. The prescribed dose of reirradiation was 50 Gy in 25 fractions over 5 weeks for 18 patients and 60 Gy in 30 fractions over 6 weeks for 1 patient. Results. Five patients could not receive the prescribed dose of reirradiation. The response rate was 43% among the 14 patients who received the prescribed dose of reirradiation. The overall 1-year and 2-year Kaplan-Meier survival rates were 26% and 11%, respectively, and the median survival time was 7.1 months. The median survival times associated with intervals between the initial irradiation and reirradiation of less than 12 months, 12-18 months, and more than 18 months were 2.1, 7.1, and 11.5 months, respectively. There were significant differences in survival between patients with an interval of less than 12 months and those with an interval of 12-18 months, and between those with an interval of less than 12 months and those with an interval of more than 18 months (generalized Wilcoxon method; P < 0.05 for both). Grade 3 radiation pneumonitis and grade 2 radiation esophagitis occurred in 1 and 3 patients, respectively. Conclusion. Reirradiation is considered to contribute to salvage in selected patients with relapsed non-small-cell lung cancer. Patients with a long interval after the initial irradiation are good candidates for reirradiation. On the other hand, patients with Eastern Cooperative Oncology Group (ECOG) performance status 3 were not goodcandidates. © The Japan Society of Clinical Oncology 2005.

引用

页码：247 / 250

页数：3

共 15 条

[1]

Furuse K., Fukuoka M., Kawahara M., Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer, J Clin Oncol, 17, pp. 2692-2699, (1999)

[2]

Komaki R., Seiferheld W., Curran W., Sequential vs concurrent chemotherapy and radiation therapy for inoperable non-small cell lung cancer (NSCLC): Analysis of failures in a phase III study (RTOG 94-10) (abstract), Proc Am Soc Ther Radiat Oncol (ASTRO), 48, (2000)

[3]

Hainsworth J.D., Burris III H.A., Litchy S., Gemcitabine and vinorelbine in the second-line treatment of nonsmall cell lung cancer, Cancer, 88, pp. 1353-1358, (2000)

[4]

Socinski M.A., Schell M.J., Bakri K., Second-line, low-dose, weekly paclitaxel in patients with stage III/A/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel, Cancer, 95, pp. 1265-1273, (2002)

[5]

Gonzalez C.M., Aramendia J.M., Salgado E., Second-line chemotherapy with irrinotecan and vinorelbine in stage IIIB and IV non-small-cell lung cancer: A phase II study, Am J Clin Oncol, 25, pp. 480-484, (2002)

[6]

Serke M., Schoenfeld N., Loddenkemper R., Weekly docetaxel as second-line chemotherapy in advanced non-small cell lung cancer: Phase II trial, Anticancer Res, 24, pp. 1211-1216, (2004)

[7]

Thames H.D., Withers H.R., Peters L.J., Changes in early and late radiation responses with altered dose fractionation:implications for dose-survival relationship, Int J Radiat Oncol Biol Phys, 8, pp. 219-226, (1982)

[8]

Thames H.D., Peters L.J., Withers H.R., Accelerated fractionation vs hyperfractionation: Rationales for several treatments per day, Int J Radiat Oncol Biol Phys, 9, pp. 127-138, (1983)

[9]

Withers H.R., Peters L.J., Taylor J.M.G., Late normal tissue sequelae from radiation therapy for carcinoma of the tonsil: Patterns of fractionation study of radiobiology, Int J Radiat Oncol Biol Phys, 33, pp. 563-568, (1995)

[10]

Okamoto Y., Murakami M., Yoden E., Reirradiation for locally recurrent lung cancer previously treated with radiation therapy, Int J Radiat Oncol Biol Phys, 52, pp. 390-396, (2002)

← 1 2 →